Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Alnylam Shares Plunge as a Drug Candidate Is Discontinued NEW YORK (TheStreet) -- Shares of Alnylam Pharmaceuticals (ALNY) were down 43.03% to $40.75 in after-hours trading on Wednesday after the biopharmaceutical company stopped development of its drug revusiran.
Alnylam suspends dosing in bleeding disorder study after patient death - https://finance.yahoo.com/news/alnylam-suspends-dosing-bleeding-disorder-121149798.html
Alnylam's genetic disease drug clears key study, shares soar - https://finance.yahoo.com/news/alnylams-genetic-disease-drug-clears-121442063.html
About RNAi RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its discovery has been heralded as “a major scientific breakthrough that happens once every decade or so,” and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines, known as RNAi therapeutics, is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam’s RNAi therapeutic platform, function upstream of today’s medicines by silencing messenger RNA (mRNA) – the genetic precursors – that encode for disease-causing proteins, thus preventing them from being made. This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases.
